🇺🇸 FDA
Pipeline program

Anti-GD2-800CW

SP_PS21DIN

Phase 2 small_molecule active

Quick answer

Anti-GD2-800CW for Neuroblastoma is a Phase 2 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
AXIM BIOTECHNOLOGIES, INC.
Indication
Neuroblastoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials